1. Home
  2. NEE vs NVO Comparison

NEE vs NVO Comparison

Compare NEE & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextEra Energy Inc.

NEE

NextEra Energy Inc.

N/A

Current Price

$80.91

Market Cap

172.4B

Sector

Utilities

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$42.12

Market Cap

199.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEE
NVO
Founded
1925
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.4B
199.4B
IPO Year
2003
2001

Fundamental Metrics

Financial Performance
Metric
NEE
NVO
Price
$80.91
$42.12
Analyst Decision
Buy
Hold
Analyst Count
12
11
Target Price
$95.67
$51.00
AVG Volume (30 Days)
9.8M
8.9M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
2.65%
3.19%
EPS Growth
N/A
N/A
EPS
1.04
N/A
Revenue
$14,256,000,000.00
N/A
Revenue This Year
$15.92
N/A
Revenue Next Year
$8.48
$3.70
P/E Ratio
$77.92
$13.60
Revenue Growth
N/A
N/A
52 Week Low
$69.40
$35.12
52 Week High
$98.75
$64.16

Technical Indicators

Market Signals
Indicator
NEE
NVO
Relative Strength Index (RSI) 30.13 35.01
Support Level $80.75 $41.05
Resistance Level $84.38 $48.15
Average True Range (ATR) 1.17 0.86
MACD -0.10 -0.34
Stochastic Oscillator 7.29 2.30

Price Performance

Historical Comparison
NEE
NVO

About NEE NextEra Energy Inc.

NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to over 6 million customer accounts in Florida and owns 36 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with nearly 40 GW of generation capacity, including natural gas, nuclear, wind, and solar.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: